Over 20 Targanta-Related Posters and Presentations Accepted to Meeting
CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Targanta Therapeutics Corporation today announced that 23 presentations will showcase its lead antibiotic candidate, oritavancin, and its antibiotic drug discovery platform at the upcoming 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Chicago, September 17-20, 2007.
Thomas Parr, Ph.D., Chief Scientific Officer of Targanta Therapeutics commented on the meeting: "We are very proud of the body of data being presented on behalf of Targanta at ICAAC this year-a true testament, we believe, to the efforts and expertise of our scientists and collaborators. We continue to be encouraged by the breadth of data supporting the differentiating characteristics of oritavancin and are pleased to be able to present for the first time promising data on our pre-clinical osteomyelitis program."
Throughout the meeting, multiple posters will highlight the in vitro activity of oritavancin, Targanta's investigational antibiotic for the treatment of gram-positive infections, against a wide spectrum of antibiotic susceptible and resistant gram-positive bacteria. In addition, two presentations at ICAAC will highlight Targanta's proprietary drug discovery platform, which utilizes bisphosphonate prodrugs of antibiotics to generate molecules that deliver antibiotics directly to the bone.
The following abstracts have been accepted for poster or slide presentation at ICAAC:
Date Time Number Type Author Title
Monday, 12:00- A-49 Poster Lehoux PK-PD of Oritavancin
Sept. 17 1:00PM CDT (ORI) Against
(SP) in a Murine-Pneumonia
|SOURCE Targanta Therapeutics Corporation|
Copyright©2007 PR Newswire.
All rights reserved